AU2022386164A1 - Protein tyrosine phosphatase inhibitors and methods of use thereof - Google Patents

Protein tyrosine phosphatase inhibitors and methods of use thereof Download PDF

Info

Publication number
AU2022386164A1
AU2022386164A1 AU2022386164A AU2022386164A AU2022386164A1 AU 2022386164 A1 AU2022386164 A1 AU 2022386164A1 AU 2022386164 A AU2022386164 A AU 2022386164A AU 2022386164 A AU2022386164 A AU 2022386164A AU 2022386164 A1 AU2022386164 A1 AU 2022386164A1
Authority
AU
Australia
Prior art keywords
hydroxy
dihydro
benzothiopyran
fluoro
trione
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
AU2022386164A
Other languages
English (en)
Inventor
Andrew Bogdan
Christos ECONOMOU
Jennifer M. Frost
Philip R. Kym
Spencer O. Scholz
Zhaoming Xiong
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Calico Life Sciences LLC
Original Assignee
Calico Life Sciences LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Calico Life Sciences LLC filed Critical Calico Life Sciences LLC
Publication of AU2022386164A1 publication Critical patent/AU2022386164A1/en
Assigned to CALICO LIFE SCIENCES LLC reassignment CALICO LIFE SCIENCES LLC Request for Assignment Assignors: ABBVIE INC., CALICO LIFE SCIENCES LLC
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/433—Thidiazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
AU2022386164A 2021-11-11 2022-11-10 Protein tyrosine phosphatase inhibitors and methods of use thereof Pending AU2022386164A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202163278336P 2021-11-11 2021-11-11
US63/278,336 2021-11-11
PCT/US2022/049581 WO2023086495A1 (en) 2021-11-11 2022-11-10 Protein tyrosine phosphatase inhibitors and methods of use thereof

Publications (1)

Publication Number Publication Date
AU2022386164A1 true AU2022386164A1 (en) 2024-05-23

Family

ID=84887566

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2022386164A Pending AU2022386164A1 (en) 2021-11-11 2022-11-10 Protein tyrosine phosphatase inhibitors and methods of use thereof

Country Status (8)

Country Link
US (1) US20250042894A1 (cg-RX-API-DMAC7.html)
EP (1) EP4430039A1 (cg-RX-API-DMAC7.html)
JP (1) JP2024543451A (cg-RX-API-DMAC7.html)
CN (1) CN118556055A (cg-RX-API-DMAC7.html)
AU (1) AU2022386164A1 (cg-RX-API-DMAC7.html)
CA (1) CA3236853A1 (cg-RX-API-DMAC7.html)
MX (1) MX2024005656A (cg-RX-API-DMAC7.html)
WO (1) WO2023086495A1 (cg-RX-API-DMAC7.html)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2024243441A1 (en) 2023-05-24 2024-11-28 Kumquat Biosciences Inc. Heterocyclic compounds and uses thereof

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UA94921C2 (en) * 2005-12-08 2011-06-25 Новартис Аг 1-orthofluorophenyl substituted 1, 2, 5-thiazolidinedione derivatives as ptp-as inhibitors
TWI888352B (zh) * 2018-06-21 2025-07-01 美商嘉來克生命科學有限責任公司 蛋白質酪胺酸磷酸酯酶抑制劑及其使用方法
KR102983496B1 (ko) * 2019-03-14 2026-06-29 칼리코 라이프 사이언시스 엘엘씨 단백질 티로신 포스파타제 억제제 및 이의 사용 방법
MX2022007441A (es) * 2019-12-18 2022-09-02 Calico Life Sciences Llc Inhibidores de proteína tirosina fosfatasa y sus métodos de uso.

Also Published As

Publication number Publication date
CN118556055A (zh) 2024-08-27
JP2024543451A (ja) 2024-11-21
EP4430039A1 (en) 2024-09-18
CA3236853A1 (en) 2023-05-19
MX2024005656A (es) 2024-08-06
US20250042894A1 (en) 2025-02-06
WO2023086495A1 (en) 2023-05-19

Similar Documents

Publication Publication Date Title
US12227484B2 (en) Inhibitors of PARG
EP3580224B1 (en) Ask1 inhibiting agents
WO2023201044A2 (en) Jak inhibitor analogs, formulations, and uses thereof
AU2023358081A1 (en) Novel bicyclic heterocyclyl compounds and use thereof
KR20210016344A (ko) 신규한 화합물
US11236086B2 (en) Substituted pyrrolopyridines as inhibitors of activin receptor-like kinase
EP3865474A1 (en) Modulators of the cystic fibrosis transmembrane conductance regulator protein and methods of use
JP6807054B2 (ja) 環状アミン誘導体及びその医薬用途
EP4107153A1 (en) Compounds
TW201204346A (en) Novel hydroxamic acid derivative
EA019488B1 (ru) Ингибиторы limk2 и способы их применения
BR112020013141A2 (pt) óxi-fluoropiperidina como inibidor de quinase
WO2021079196A2 (en) Mettl3 modulators
RS62271B1 (sr) Inhibitori 3-fosfoglicerat dehidrogenaze i njihova upotreba
US20250019374A1 (en) Protein tyrosine phosphatase inhibitors and methods of use thereof
EP3400226A1 (en) Derivatives of pyrroloimidazole or analogues thereof which are useful for the treatment of inter alia cancer
CA3168222A1 (en) Pyrrolopyrimidine derivatives and pharmaceutical composition for preventing or treating protein kinase-related disease comprising the same as an active ingredient
US20240092761A1 (en) Quinazoline compounds and methods of use
WO2023086495A1 (en) Protein tyrosine phosphatase inhibitors and methods of use thereof
WO2011102404A1 (ja) イミダゾール誘導体
EP4011865A1 (en) Bridged heterocyclyl-substituted pyrimidine compound, preparation method therefor, and pharmaceutical use thereof
WO2019022235A1 (ja) 円形脱毛症の治療剤又は予防剤
TWI652265B (zh) 氮雜吲哚衍生物
AU2020421654A1 (en) RORγt inhibitor, preparation method thereof and use thereof
CA3070717C (en) Inhibitors of plasma kallikrein and uses thereof

Legal Events

Date Code Title Description
PC1 Assignment before grant (sect. 113)

Owner name: CALICO LIFE SCIENCES LLC

Free format text: FORMER APPLICANT(S): CALICO LIFE SCIENCES LLC; ABBVIE INC.